Selektivní kinázové inhibitory na bázi pyrazolo[1,5-a]pyrimidinu Dr. Kamil Paruch Schering-Plough Research Institute, Kenilworth, NJ, USA Ústav chemie, Masarykova univerzita, Brno • CDK inhibitor SCH 727965 (dinaciclib) • CHK1 inhibitor SCH 900776 CDKs participate in cell cycle progression and cellular transcription Sausville, EA. Trends Molec Med 8: S32, 2002 Sausville, EA. Trends Molec Med 8: S32, 2002 1 Targeting the cell cycle and CDKs • Inhibition of CDK activity is an attractive therapeutic concept • Anticipated effects, based on mechanism, include: Tumor cell-specific apoptosis Reversible inhibition of proliferation in normal cells • Phenotypes confirmed by extensive experimental validation (siRNA, dominant negatives and reference inhibitors) • Activity versus CDK2 and CDK1 shown to be essential for efficacy 2 Target candidate profile 1. Potent, selective inhibitor of CDK2 and CDK1 2. Broad spectrum of activity (in vitro and in vivo) 3. Differential effects on tumor versus normal cells Apoptosis in tumors Transient arrest in normal tissues Non-genotoxic MOA 4. Acceptable therapeutic index Superior to competition and standards of care 5. Suitable for iv formulation and infusion 6. Reversible and manageable side-effects 3 Selectivity issue CDK2 vs. GSK3b 4 Lead finding • Early effort: synthesis based on molecular modeling: chemotypes capable of binding to the protein backbone (e.g. indazoles) acceptable in vitro activity (< 50 nM), poor potency in the cell. • Variety of compound libraries purchased to improve hit rate in kinase inhibitor programs. • CDK2 actives found in Biofocus kinase-directed libraries. Pyrazolo[1,5-a]pyrimidines N Cl Cl N F N N Compound A CDK2 IC50 = 0.50 uM HN N 5 Imidazo[1,2-a]pyrazines N N Compound B CDK2 IC50 = 0.8 uM HN N Proposed binding modes Cl HO NH N N N N H N Cl Cl 5 N CO2H 3 N H O O N H Leu 83 7 N N N H H N O O N N H Leu 83 Crystal structure of A in CDK2 Purvalanol B CDK2 IC50 = 0.009 uM Compound A CDK2 IC50 = 0.50 uM • Initial SAR Plan: Increase potency by incorporating 3-substitution. 6 3-Substitution improves potency Br N Cl Cl N N N HN Compound A CDK2 IC50 = 0.50 uM Thym. IC50 = 21 uM Cl HN N N Follow-up SAR plan: evaluate similar heterocyclic cores: Br Br Br N N N HN 7 N N N N HN N HN N Compound A1 CDK2 IC50 = 0.003 uM Thym. IC50 = 0.48 uM Synthesis of pyrazolo[1,5-a]pyrimidines R NH2 R OCH3 + O N H O N AcOH 85% R DMAP N N N N N pyr. O Cl POCl3 80% 3 2 1 H N 4 NBS CH3CN NH2 R 95% Br N N N N DIPEA dioxane 91% HN R = H: 6 N R N Br N N Cl 5 IC50 = 0.011uM thym. IC50 = 0.39 uM Bioorg. Med. Chem. Lett. 2007, 17, 6216. 8 Synthesis of pyrazolo[1,5-a]pyridines 1. O H2N O S Ph O 7 K2CO3, DMF Ph air/O2 Ph N H2N CH2Cl2 CO2Et N+ OR- 8 Ph n-BuLi N N 2. H2SO4, heat 9 39% N N ICH2CH2I 55% I Ph HN 13 NH2OH ZnCl2 NaOAc Br Ph NBS N N N 80% H Cs2CO3 Ph Ph PhCH3 Ph N N CH3CN N 80% 12 N IC50 = 1.87 uM 9 N then NaBH3CN 65% BINAP 76% Br N N Pd(OAc)2 Ph N CHO 10 Ph Ph 11 pyrazolopyrimidine IC50 = 0.011uM thym. IC50 = 0.39 uM Bioorg. Med. Chem. Lett. 2007, 17, 6216. Synthesis of imidazo[1,2-a]pyrazines N O R Br R N N + N CONH2 15 14 HN CH3CN 80% O R N H Br- N+ CH3 N HN 77% N O 17 16 pyr. POCl3 40% NH2 Br R N N N DIPEA dioxane N 78% R = H: 20 IC50 = 0.44uM thym. IC50 = 2.0 uM 10 NBS R N N N HN Br R N N Cl 19 CH3CN 96% N N Cl 18 pyrazolopyrimidine IC50 = 0.011uM thym. IC50 = 0.39 uM Bioorg. Med. Chem. Lett. 2007, 17, 6216. Synthesis of imidazo[1,2-a]pyridines Br N H2N 1. red. 2. Br NO2 21 Br N CHO K2CO3 57% PhB(OH)2 N NH2 22 Pd(PPh3)4 K3PO4 DME, H2O 91% AcCl N N NH2 N N pyr. 78% NHAc 24 23 NBS CH3CN 89% Br CHO N N N Br HCl N HN ZnCl2 26 N IC50 = 0.70 uM 11 then NaBH3CN 49% EtOH 93% N NHAc 25 pyrazolopyrimidine IC50 = 0.011uM thym. IC50 = 0.39 uM Bioorg. Med. Chem. Lett. 2007, 17, 6216. CDK2 activity in various heterocyclic cores Br N N HN Br Br N < < N HN N N HN N << Br N N N HN • focus on SAR of pyrazolo[1,5-a]pyrimidines 12 Validating the concept Does the lead series give the desired activity in cell culture? Can we derive a therapeutic index? Can the desired activity be demonstrated in vivo? 13 Initial lead compound Br 5 N F 3 N N 7 HN N+ O– In Vitro IC50’s (uM) CDK2/E = 0.031 CDK2/A = 0.030 CDK1 = 0.045 CDK4 = 0.045 MAPK = 1.2 GSK3b = 0.15 3A4, 2D6, 2C9, 2C19 > 30 uM In-Cell, thy uptake, A2780 IC50 (10% FBS) = 0.16 uM IC90 (10% FBS) = 0.29 uM hERG Rb:17% @ 1.5 uM Rb: 44% @ 5 uM VC: IC50 = 3.2 uM Compound 27 Mouse PK (IV/PO, 5 mpk) AUC = 8.4 uM.hr Cmax = 5.8 uM IV t1/2 = 2.4 hrs (NOEL) Rat PK (IV/PO, 5/10 mpk) PO AUC = 34.5 uM.hr Cmax = 4.4 uM IV t1/2 = 5.9 hrs clearance = 18 mL/min/kg (IV, PO NOEL) Monkey PK (IV/PO, 1/5 mpk) PO AUC = 29.9 uM.hr Cmax = 2.5 uM IV t1/2 = 11.0 hrs (IV: NOEL; PO: 2/3 diarrhea) • Efficacy: A2780 (ovarian): 96% I @ 40 mpk, qd; MiaPaCa (pancreatic): 77% I @ 40 mpk, qd. • Increasing exposure with increasing dose; physical properties appear to limit Cmax. • Poor solubility has precluded development of an IV formulation. 14 In-cell activity/therapeutic index Compound 27 Continuous Exposure Assays A2780 (Tumor) WS1 (Normal) Compound 27 Pulsed Exposure Assays • Expose cells to vehicle, IC50, IC90, 2 x IC90 for 24 hrs • Wash out compound, follow recovery of culture • Support of efficacy (putative trough/exposures) • Cell cultures show very distinct responses 15 A2780 WS1 Apoptosis Cell cycle delay/arrest Program progression Is the current lead appropriate to progress for further evaluation? What are the key issues? What approach do we take to resolve them? 16 Improving the potency of the lead compound 3-Position: • Tight SAR. • Br, Cl, ethyl optimal. • Kinase selectivity domain. 5-Position: • Variety of polar/nonpolar functionality tolerated. • Greatest potential for increases in potency. • High affinity for –OH substitution. • Substitution influences selectivity. 7-Position: • Solvent exposed; wide variety of functionality tolerated. • Potency improvements with modulation of physical characteristics. • Substitution influences selectivity. 17 3-Substitution R N • Tight SAR; only small hydrophobic substituents tolerated. • 3-Ethyl similar to 3-Br. N N HN N # R CDK2 IC50 Thy. IC50 # 8 Cl 0.021 uM 0.8 uM 17 0.011 0.48 18 0.62 --- 19 0.072 1.8 20 12 0.008 0.76 21 13 1.2 --- 22 14 0.071 2.4 23 15 0.37 --- 16 0.048 1.1 ; o-F Br 9 10 CN ; 4-pyr. R CDK2 IC50 Thy. IC50 0.71 --- OH ; 4-pyr. 2.7 --- OCH3 3.8 --- 0.45 --- 34 --- 13.4 --- 0.049 3.5 24 0.13 1.3 25 1.3 --- CF3 OH 11 18 CH3 N(CH3)2 NH 2 CN Bioorg. Med. Chem. Lett. 2007,17, 6220. 7-Substitution Br N • Solvent exposed; wide variety of functionality tolerated. • Potency improvements with modulation of physical characteristics. N N HN # 26 R R= N+ CDK2 Thy. RR AUC # 0.034 0.14 17.7 32 R= CDK2 Thy. RR AUC 0.014 uM 0.052 uM 3.9 uM.hr 0.013 0.024 1.7 0.18 0.029 0.2 0.19 0.069 0.018 0.15 0.5 0.008 0.09 1.1 O– NH N 0.032 0.28 6.0 N O N 28 0.005 0.18 1.1 34 (o-F) S N N N OH 29 H N 33 N 27 0.016 0.1 0.4 35 (o-F) S N N 30 N 0.019 0.12 1.8 36 S OH NH2 O O – 31 N+ O 0.018 OEt 19 0.026 11.4 37 NH2 Bioorg. Med. Chem. Lett. 2007,17, 6220. Br R 5-Substitution: aryl N N N • Variety of polar/nonpolar functionality tolerated. HN • Greatest potential for increases in potency. N # R= 48 CDK2 IC50 Thy. IC50 # CDK2 IC50 Thy. IC50 RR AUC 0.011 uM 0.38 uM N-oxide 48A 0.034 uM 0.14 uM 17.7 uM.hr 0.011 0.48 N-oxide 7 0.031 0.21 15.0 0.003 0.5 N-oxide 50A 0.011 0.17 7.9 0.037 1.2 N-oxide 51A 0.09 0.30 11.4 0.017 0.34 N-oxide 52A 0.047 0.15 tbd 0.013 0.75 N-oxide 53A 0.035 0.22 9.2 0.008 0.48 N-oxide 54A 0.016 0.16 12.0 0.032 1.6 F 49 Cl 50 F 51 52 NC 53 54 S O N 55 20 S Bioorg. Med. Chem. Lett. 2007,17, 6220. 5-Substitution: alkyl Br R N N N HN N # R= CDK2 IC50 Thy. IC50 56 0.018 0.52 57 0.017 0.95 0.038 1.4 0.020 1.3 0.013 OH 58 59 60 61 62 63 21 HN O HN # CDK2 IC50 Thy. IC50 RR AUC N-oxide 56A 0.12 uM 0.87 uM --- N-oxide 57A 0.09 0.7 --- 0.2 N-oxide 60A 0.015 0.12 5.8 uM.hr 0.016 0.16 N-oxide 61A 0.025 3.1 0.0 0.021 0.38 N-oxide 62A 0.028 0.008 0.045 N-oxide 1.4 Compounds with improved potency/PK Br Br N F O HN HN N+ – O N N N N N N HN 22 N Br N N+ – O N+ – O O Compound 27 CDK2/A IC50 = 0.030 uM Thy. IC50 = 0.16 uM Compound 28 CDK2/A IC50 = 0.016 uM Thy. IC50 = 0.16 uM Compound 31 CDK2/A IC50 = 0.018 uM Thy. IC50 = 0.025 uM Rat PK (IV/PO, 5/10 mpk) PO AUC = 34.5 uM.hr IV t½ = 5.9 hrs Monkey PK (IV/PO, 1/5 mpk) PO AUC = 29.9 uM.hr IV t1/2 = 11.0 hrs Rat PK (IV/PO, 5/10 mpk) AUC = 28 uM.hr IV t½ = 2.1 hr Monkey PK (IV/PO, 2/10 mpk) AUC = 71 uM.hr t½ = 12 hrs Rat PK (IV/PO, 2/10 mpk) AUC = 15 uM.hr IV t½ = 3.6 hr Monkey PK (IV/PO, 0.5/1 mpk) AUC = 10 uM.hr t½ = 12 hrs Br R 5-Position: alcohol substitution N N N HN N OH OH N N N F Compound 70 CDK2 IC50 = 0.011 uM Thy. IC50 = 0.48 uM Compound 71 CDK2 IC50 = 0.063 uM Thy. IC50 = 2.5 uM Compound 72 CDK2 IC50 = 0.027 uM Thy. IC50 = 0.26 uM Compound 73 CDK2 IC50 = 0.0004 uM Thy. IC50 = 0.006 uM H N H N H N H N OH Compound 74 CDK2 IC50 = 0.063 uM Thy. IC50 = 1.1 uM Compound 75 CDK2 IC50 = 0.018 uM Thy. IC50 = 0.85 uM Compound 76 CDK2 IC50 = 0.006 uM Thy. IC50 = 0.2 uM OH Compound 77 CDK2 IC50 = 0.0003 uM Thy. IC50 = 0.002 uM • Alcohol substitution improves potency and solubility, but increases rate of clearance and decreases exposure 23 What is the optimal profile for a CDK inhibitor? • Series with distinct properties were identified: Compound 7: average potency, good PK Compound 31: improved in-cell potency, excellent PK Compound 73A: high potency, rapid clearance • How do they compare to known CDK inhibitors? BMS-387032: average potency, rapid clearance Flavopiridol: average potency, rapid clearance • How do we identify the optimal profile (potency, PK)? Br Br N N N N N N N N HN OH O S HN S N N + O– + N O N H O– O Compound 31 24 Compound 73A BMS-387032 NH In vivo screening paradigm • Goal: identification of optimal profile • Readout: efficacy below MTD in mouse Test Compounds Mouse mini-tox (ip, qdx7) MTD determination Efficacy (A2780 xenograft ip, qdx7) Establish effective dose/plasma concentration “Efficacy Arm” Single Dose Mouse PK (IP) Evaluate Index MTD determination Evaluate exposures and multiples Superior Compounds Rising Dose Rat/Dog (iv) Confirm index/multiples Candidate 25 Rat mini-tox/PK (iv) “Safety Arm” Initially evaluated compounds Structure Compound # CDK2 (CDK1) IC50 [uM] 31 0.018 (0.12) In-Cell IC50 [uM] mouse IP MTD [mpk] MED* (%I) TI** AUC (uM.hr) Cmax (uM) 10 @ 5 mpk 9@5 mpk 1.4@ 5 mpk 6@5 mpk 6 @ 20 mpk 8 @ 20 mpk Br N N N HN N 0.025 5 <5 mpk (68%) 1-2 + O – O Br N N N N OH 73A HN 0.001 (0.008) 0.003 20 <4 mpk (73%) ~5 + N O– N O S O S N N H BMS-387032 NH 0.011 (0.068) 0.039 50 25 mpk (58%) 2-3 *MED – Minimum Effective Dose (>50% inhibition in A2780 efficacy); **TI (therapeutic index) = MTD/MED; MTD: dose (ip, qdx7) giving 20% BW loss. 26 • Amino alcohol series (high potency, short t½) gives best therapeutic index. • High potency, short t½ contrary to conventional wisdom What is the rationale for the activity seen with compound 73A? Identification of SCH 727965 Structure Compound # CDK2 (CDK1) IC50 [uM] In-Cell IC50 [uM] mouse IP MTD [mpk] MED* (%I) TI AUC (uM.hr) Cmax (uM) 1.4 @ 5 mpk 6@5 mpk 1.4 @ 5 mpk 2@5 mpk Br N N N N OH 73A HN 0.001 (0.008) 0.003 20 <4 mpk (73%) ~5 N+ N O– N N N OH SCH 727965 HN 0.001 (0.006) 0.004 60 3 mpk** (48%) >10 N+ O– *MED – Minimum Effective Dose (>50% inhibition in A2780 efficacy) N N N N N OH HN vs. N 27 N N O HO HN N • in vivo differentiation of compounds with nearly identical in vitro profile O ACS Med. Chem. Lett. 2010, 1, 204. SCH 727965: in vitro properties In Vitro N N N N OH HN SCH 727965 N+ O– A/CDK2 IC50 = 0.001 uM B/CDK1 IC50 = 0.004 uM p35/CDK5 IC50 = 0.001 uM UBI Kinase Profiler – No issues PanLabs – No issues GPCR – No issues D/CDK4 IC50 = 0.1 uM H/CDK7 IC50 = 0.07 uM GSK3b IC50 = 0.78 uM MAPK IC50 = 4.1 uM CYP – No issues hERG (VC) – 5% @ 1 uM Invest. CV – No issues up to ~0.37 uM In Cell IC50 (A2780) = 0.004 uM Marker IC50 (phospho-Rb) = ~0.01 uM 2 hour apoptosis = 0.025 uM (BMS-387032 = 1 uM) Cell Line Survey (106 cell lines, NCI-60 plus others) Multiple assays (FACS, markers, viability, apoptosis) 100% arrest; >85% apoptosis. Predominant tumor cell response - apoptosis Normal cell response (WS-1) - cell cycle arrest, little apoptosis CDK2/cyclin A + SCH 727965 28 Mol. Cancer Ther. 2010, 9, 2344. In vivo efficacy: SCH 727965 is active < MTD A2780 (ovarian cancer) A549 (lung cancer) RPMI 8226 (multiple myeloma) • same model used for preclinical studies of Velcade • complete cures in 20 mpk group (no regrowth of tumor) • complete cures in 20 mpk group (no regrowth of tumor) • no effect on RBC, platelets • mild reversible myelosupression 29 CHK1 inhibitors template-based approach N N R5 N N OH R3 N N R6 HN R7 SCH 727965 CHK1 IC50 : 25 000 nM CDK2 IC50 = 1 nM N N CHK1 inhibitor? O Antimetabolites induce activation (and phosphorylation) of CHK1 kinase CHK1 inhibition + HU (or gemcitabine or cytarabine) induce DNA damage and cell death 30 NH2 R5 OCH3 + O N H O O N H O O + N H O OEt O + N H O R3 N R3 N 2 steps NHR7 OH BocN R3 N N N N OH R3 = H, alkyl, aryl NH2 BocN OEt O 31 O + N H N BocN R3 N N N N N N CHK1 kinase CDK2 kinase N N R6 NHR7 NH2 R3 BocN N R5 NH2 R3 OEt N N NHR7 NH2 OCH3 + R3 N N R6 R5 R5 N N N OH BocN BocN N N N BocN N N N R6 N N R6 NHR7 NHR7 OH R3 N alkyl, (het)aryl BocN N BocN NBS N N Br N N N CH3CN R R R = OH, Cl, NH2 BocN N BocN Br2 N N N N N Br t-BuNH2 R R R = OH, NH2 R = OH, NH2 N BocN 5 steps N Br N N NH2 32 Bioorg. Med. Chem. Lett. 2011, 21, 471. HN R3 N R6 N N NH2 HN N N N N N N NH2 CHK1 IC50 = 100 nM CDK2 IC50 = 22 000 nM CHK1 inhibitors template-based approach N N HN N OH N HN N N N N N HN N NH2 N N Br N N NH2 SCH 900776 SCH 727965 CHK1 IC50 : 25 000 nM CDK2 IC50 = 1 nM N N N O CHK1 IC50 = 100 nM CDK2 IC50 = 22 000 nM SCH 900776 + HU (or Gem or Ara-C) induce DNA damage and cell death in vivo 33 Mol. Cancer Ther. 2011, doi:10.1158/1535-7163.MCT-10-0324. CHK1 IC50 < 10 nM CHK1 small molecule inhibitor + HU (or Gem or Ara-C) induce DNA damage and cell death NH2 O HO N F HO NH2 N O F R O O F HO gemcitabine • inhibits RNR (as triphosphate) • gets incorporated into DNA • relatively toxic • limited stability N N O F gem analogs (WO 2009/061781 A1) • gem-like phenotype in combination with CHK1 inhibitor • no DNA incorporation current effort • compounds with targeted biological activity synthetic lethal treatment CHK1 + DNA polymerase-a inhibition induce DNA damage and cell death Taricani, L.; Shanahan, F.; Parry, D. Cell Cycle 2009, 8, 482. 34 The End